Clinical trials: POAG
Primary Open Angle Glaucoma
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy).
- Trial name
- NCT02406833
- Testing
- TGF-β2 antisense oligonucleotide, Trabeculectomy
- Where
- 3 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Isarna Therapeutics GmbH
Visual Field, OCT Angiography
Visual Field Changes and OCT Angiographic Chorioretinal Changes in Patients With Primary Open Angle Glaucoma
This study aimed to assess the correlation between visual field changes and optical coherence tomography (OCT) angiography changes of retinal nerve fiber layer in patients with primary open angle glaucoma.
- Conditions
- Visual Field, OCT Angiography, Chorioretinal Changes, Primary Open Angle Glaucoma
- Trial name
- NCT06978101
- Testing
- POAG group, Control group
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma (POAG)
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.
- Trial name
- COMPASS-XT (NCT02700984)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Glaucoma, Glaucoma, Open-Angle
Pigment Dispersion Syndrome With and Without Glaucoma
To compare patients having PDS without and with OH or GL by documenting and following the clinical features and course of their disease and evaluating the patient's performance on a variety of diagnostic tests.
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
- Trial name
- NCT00001152
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Eye Institute (NEI)
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More
Increased intraocular pressure (IOP) has been identified as the most important risk factor for the development and the progression of glaucoma.
- Trial name
- NCT01979913
- Testing
- Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Dr. Anton Hommer
Glaucoma
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
- Trial name
- STAR-V (NCT05024695)
- Testing
- MINIject™ Implant
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 975 people
- Sponsor
- iSTAR Medical
Primary Open-Angle Glaucoma
PIO Laser Sclerectomy IOP SLT Sclerectomy
The main objective of this study is to characterize the changes in IOP over 24 hours after selective trabeculoplasty SLT (before and 1 and 6 months after treatment, decreased IOP, type of rhythm, mesor, acrophase, amplitude).
- Trial name
- PIO laser SPNP (NCT01798732)
- Testing
- Selective Laser Trabeculoplasty (Tango Laser, Ellex)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Grenoble
Retinal Degeneration, Primary Open-Angle Glaucoma
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall.
- Trial name
- NCT02144103
- Testing
- Subtenon administration of autologous ADRC, Liposuction, ADRC isolation
- Where
- 2 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Glaucoma, Primary Open Angle
Excimer Laser Trabeculostomy Glaucoma Treatment Study
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG) undergoing cataract surgery
- Trial name
- ELTGTS (NCT04899063)
- Testing
- ELIOS Procedure
- Where
- 20 sites in United States
- Volunteers
- 318 people
- Sponsor
- Elios Vision, Inc.
Subject With Primary Open-angle Glaucoma (POAG)
A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent
The purpose of this study is to assess the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.
- Trial name
- NCT01252914
- Testing
- iStent Supra Stent
- Where
- Armenia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Alzheimer's Disease, Glaucoma
Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head.
- Trial name
- NCT00691340
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Open-angle Glaucoma, Ocular Hypertension
Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00471068
- Testing
- Travatan, Cosopt
- Where
- Portugal
- Volunteers
- 46 people
- Sponsor
- Alcon Research
Glaucoma, Eye Diseases
A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma
Prospective, unmasked, evaluation of the iStent in patients that have primary open-angle glaucoma (OAG). Stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.
- Conditions
- Glaucoma, Eye Diseases, Glaucoma, Open-Angle
- Trial name
- SY (NCT00911924)
- Testing
- iStent
- Where
- 13 sites in Armenia, Austria and 4 more
- Volunteers
- 112 people
- Sponsor
- Glaukos Corporation
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Primary Open Angle Glaucoma, Low Tension Glaucoma
Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma
The purpose of this study is to assess how surgical interventions in glaucoma affect 24-hour intraocular pressure, 24-hour ocular perfusion pressure, optic nerve blood flow, and retinal oxygen saturation.
- Conditions
- Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
- Trial name
- NCT02891317
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of North Carolina, Chapel Hill
Primary Open Angle Glaucoma and Cataracts
A Clinical Trial of Phacoemulsification Versus Phacoemulsification & the iStent Implantation in POAG Patients
This was a prospective, double-masked, 15-month clinical trial comparing efficacy of phacoemulsification alone to combined phacoemulsification and implantation of the iStent® trabecular micro-bypass stent in patients with primary…
- Trial name
- NCT00847158
- Testing
- phacoemulsification alone, iStent Trabecular Micro-Bypass Stent
- Volunteers
- 36 people
- Sponsor
- University of Turin, Italy
Glaucoma Open-Angle Primary, Ocular Hypertension
GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study
This observational study aims to identify early diagnostic markers of glaucomatous damage by combining functional and structural assessments.
- Trial name
- GLAUDIA (NCT07210216)
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS